Dana-Farber Cancer Institute: Immunotherapy Drug Delays Recurrence in Kidney Cancer Patients
August 19, 2021
August 19, 2021
BOSTON, Aug. 19 -- The Dana-Farber Cancer Institute issued the following news release:
Treatment with an immunotherapy drug following kidney cancer surgery, prolonged disease-free survival rates in patients at high risk for recurrence, according to an interim report of a phase 3 clinical trial of adjuvant immunotherapy in this patient population, published in the New England Journal of Medicine.
Patients who were treated for nearly a year with pembrolizumab experienced . . .
Treatment with an immunotherapy drug following kidney cancer surgery, prolonged disease-free survival rates in patients at high risk for recurrence, according to an interim report of a phase 3 clinical trial of adjuvant immunotherapy in this patient population, published in the New England Journal of Medicine.
Patients who were treated for nearly a year with pembrolizumab experienced . . .